Difficult conditions in the UK and postponed operations expected to affect Q2 for Coloplast

It will be hard to compare the figures in Coloplast's Q2 report with other periods, says Sydbank analyst Søren Løntoft Hansen, who expects the medtech company to be affected by difficult conditions in the UK and delayed operations.


An uphill battle in the UK, postponed operations due to covid-19 and a difficult basis for comparison with other quarters will be some of the most important themes in Coloplast's Q2 fiscal report, according to Danish financial institution Sydbank's Chief Equity Analyst Søren Løntoft Hansen.

"We predict that growth will be reduced by the postponement of non-urgent procedures due to covid-19. Furthermore, comparison will be difficult, since during the second quarter of last year, Coloplast was positively affected by stockpiling," he comments.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Britt Meelby Jensen wants to rebuild trust in Ambu

After a turbulent time for Ambu under Juan Jose Gonzalez’s reign, new chief executive appointee Britt Meelby Jensen aims to rebuild the trust in the medtech firm, which has downgraded its expectations seven times over the past three years.

Outgoing Ambu CEO commends colleagues

”A true privilege,” says Juan Jose Gonzalez, describing his time as CEO at Ambu, which came to an end with Thursday’s announcement that Britt Meelby Jensen would take over the role.

Further reading

Related articles

Latest news

See all jobs